NDAORALTABLET, DELAYED RELEASE
Approved
May 2005
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
2
Data completeness
6/8 — Strong
DORYX MPC (doxycycline hyclate) by Pfizer is tetracycline-class antimicrobial drug [ see ]. First approved in 2005.
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DORYX MPC is an oral delayed-release tablet formulation of doxycycline hyclate, a tetracycline-class antimicrobial drug approved in 2005. It is used to treat bacterial infections across multiple indications. The delayed-release formulation improves gastrointestinal tolerability compared to immediate-release doxycycline.
$0.146MPart D
Peak8.5 years to LOEProduct is in peak commercial phase with minimal Medicare Part D utilization, suggesting stable mature market presence with limited team expansion.
Mechanism of Action
tetracycline-class antimicrobial drug [ see ].
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Double-blind-randomized,Placebo Controlled Trial for Chemotherapy-associated Oral Mucositis Using Doxycycline Hyclate
Started May 2010
164 enrolled
Mucositis
Adapalene-BPO Gel Associated With Doxycycline Hyclate 100 mg in the Treatment of Severe Acne Vulgaris
Started Aug 2008
459 enrolled
Severe Acne Vulgaris
Career Relevance
Working on DORYX MPC offers stability in a mature, profitable product with strong patent protection through 2034, but limited expansion opportunities due to lack of clinical development and minimal competitive pressure. Career advancement will depend on maximizing market penetration and managing the transition to LOE strategy rather than launching new indications.
Brand Manager
Worked on DORYX MPC at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.